Zymewire Raises $100K to

Zymewire, the leading sales intelligence management system built exclusively for service providers in the life sciences industry, has secured $100K in new investment capital.

This funding round will support the company's ongoing mission to simplify prospecting and accelerate revenue growth for its global client base.

Headquartered in Toronto, Zymewire leverages over 15 years of AI-powered, human-curated insights on thousands of biopharma companies.

Its platform combines unique data sources, including intelligence on emerging biotech opportunities and clinical trial activity, with a suite of tools designed to help organizations manage the flow of external insights.

This empowers commercial teams with accurate, up-to-date information, enabling smarter outreach and the cultivation of more meaningful relationships with biotech customers.

The $100K investment will be strategically deployed to accelerate Zymewire's product development initiatives and expand its market presence.

The company plans to enhance its AI capabilities and broaden its reach to support an increasing number of CROs, CDMOs, and other service providers worldwide.

This capital infusion underscores the growing demand for specialized, AI-driven sales intelligence solutions within the dynamic biopharma industry.

Zymewire currently serves over 375 clients across Europe, North America, and APAC, establishing itself as a leader in a new field of B2B software that uses AI to help companies make informed decisions.

The company remains committed to delivering comprehensive industry awareness, enabling its clients to make the most informed decisions, take immediate action, and excel in their unique roles.